Review · United States
VIP peptide
Reviewed on
Approval and product status
Human physiology and a clinical trial have been studied; product approval needs a separate current check
VIP is a natural body signal. Aviptadil is synthetic VIP studied as a defined intravenous research treatment. An FDA substance record or orphan designation is not approval of a finished drug. Neither record shows that a compounded or online product matches the trial material.
What was measured in people?
- Health results · Limited
- A 196-person aviptadil trial in critical COVID-19 respiratory failure missed its prespecified day-60 primary endpoint. Other trial results do not prove a treatment benefit.
- Body changes · Limited
- A 12-person healthy-volunteer study measured a short vascular response and delayed headache during and after VIP infusion.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
This page gives no dose, injection, sourcing, product-selection, or treatment advice. A short study response does not prove long-term safety or benefit. Ask a licensed clinician about personal care.
Still unknown: These studies do not show that VIP treats COVID-19, lung disease, gut disease, or aging. The trial did not test other routes or products. The FDA records checked here identify aviptadil and two orphan designations. Both designation records say the named orphan indication was not FDA approved. Those records do not establish the approval status of every possible product or use. They also do not show that an online or compounded item matches the trial material.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“An FDA aviptadil substance record or orphan designation is drug approval.”
Misleading. A substance record identifies a substance. The two checked FDA orphan records state that the named orphan indications were not approved. Neither record approves a finished product.
Applies to: The exact FDA records checked September 12, 2026; this is not a complete product-level approval search.
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
In 12 healthy volunteers, a two-hour VIP infusion widened a head artery and increased mild delayed headache. This measured a short body response, not a health benefit. A randomized trial studied intravenous aviptadil in 196 people with critical COVID-19 respiratory failure. Its main result was whether people were alive and free from respiratory failure at day 60. That primary result did not reach statistical significance. Some other results favored aviptadil, but they do not make the main result a success.
Read all VIP peptide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 8 sources
- Discovery report for vasoactive intestinal peptide
PubMed · Science · Reference · 1970
Source accessed
- National Library of Medicine VIP terminology record
National Library of Medicine · Reference · 2026
Source accessed
- VIP infusion study in 12 healthy volunteers
PubMed · Cephalalgia · Human pharmacology · 2020
Source accessed
- Randomized aviptadil trial in critical COVID-19 respiratory failure
PubMed · Critical Care Medicine · Randomized trial · 2022
Source accessed
- FDA COVID-19 drug status page
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- FDA aviptadil substance identity record
U.S. Food and Drug Administration · Reference · 2026
Source accessed
- FDA aviptadil orphan designation for sarcoidosis
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- FDA aviptadil orphan designation for pulmonary arterial hypertension
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed